EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21

John J Schellenberg, Heather J Adam, Melanie R Baxter, James A Karlowsky, Alyssa R Golden iD, Irene Martin, George G Zhanel

Journal of Antimicrobial Chemotherapy · 02.05.2025 · 80 (5) · 1377-1385

DOI: 10.1093/jac/dkaf085 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 25.03.2025. Verfasst von John J Schellenberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, …. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Pneumococcal Infections, Pneumococcal Vaccines. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Manitoba, Shared Health, National Microbiology Laboratory-Public Health Agency of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

V116 is a novel 21-valent pneumococcal conjugate vaccine (PCV) intended for use in adults.

Objectives

To estimate current V116 serotype coverage in adult patients in Canada compared with PCV15, PCV20 and PPSV23 vaccines, and to describe isolate demographics for the eight unique serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) covered by V116.

Methods

From 2018 to 2021 inclusive, the SAVE study collected 5854 invasive pneumococcal disease (IPD) isolates as part of a collaboration between the Canadian Antimicrobial Resistance Alliance and the Public Health Agency of Canada–National Microbiology Laboratory. Serotypes were determined by Quellung reaction and antimicrobial susceptibility testing performed using the CLSI broth microdilution method.

Results

For adult patients (≥18 years), adults 50–64 years and adults ≥65 years, respectively, IPD isolate coverage was PCV15 (42.7%; 41.0%, 39.8%), PCV20 (59.0%; 60.2%, 52.2%), PPSV23 (70.4%; 75.1%, 60.0%), V116 (78.9%; 76.3%, 81.5%) and V116 plus PCV20 (92.2%; 91.0%, 89.3%). The eight unique V116 serotypes accounted for 19.7% and 26.8% of IPD isolates from adults and adults ≥65 years, respectively. Among the eight unique V116 serotypes, 15A and 23A demonstrated the highest rates of MDR (17.0% and 10.2%, respectively); 6.7% of 15A isolates were XDR.

Conclusions

V116 provided significantly (P < 0.05) greater coverage than PCV15, PCV20 and PPSV23 for adults, including older adults, across all Canadian geographic regions, and against IPD isolates with common antimicrobial resistance phenotypes, including MDR. The eight unique V116 serotypes accounted for a higher proportion of IPD isolate serotypes in patients aged ≥65 years than younger adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Streptococcus pneumoniaePneumococcal InfectionsPneumococcal VaccinesHumansCanadaMiddle AgedSerogroupAgedAdultMaleFemaleYoung AdultAdolescentMicrobial Sensitivity TestsAged, 80 and overVaccines, ConjugateAnti-Bacterial AgentsSerotyping

Substanzen

Pneumococcal VaccinesVaccines, ConjugateAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, Canada.
  • Clinical Microbiology, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada.
  • National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada.

ORCID-Profile: Alyssa R Golden

Förderung

  • University of Manitoba
  • Shared Health
  • National Microbiology Laboratory-Public Health Agency of Canada
  • Investigator-Initiated Studies Program of Merck Canada Inc
  • National Microbiology Laboratory–Public Health Agency of Canada

Zitieren

APA

Schellenberg, J. J., Adam, H. J., Baxter, M. R., Karlowsky, J. A., Golden, A. R., Martin, I., & Zhanel, G. G. (2025). Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21. Journal of Antimicrobial Chemotherapy, 80(5), 1377-1385. https://doi.org/10.1093/jac/dkaf085

Vancouver

Schellenberg JJ, Adam HJ, Baxter MR, Karlowsky JA, Golden AR, Martin I, et al. Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21. Journal of Antimicrobial Chemotherapy. 2025;80(5):1377-1385. doi:10.1093/jac/dkaf085

BibTeX
@article{Schellenberg2025,
  author = {Schellenberg, John J and Adam, Heather J and Baxter, Melanie R and Karlowsky, James A and Golden, Alyssa R and Martin, Irene and Zhanel, George G},
  title = {Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {5},
  pages = {1377--1385},
  doi = {10.1093/jac/dkaf085}
}
Kostenlos starten →